Altered systemic iron metabolism in Parkinson's disease

被引:102
作者
Logroscino, G
Marder, K
Graziano, J
Freyer, G
Slavkovich, V
LoIacono, N
Cote, L
Mayeux, R
机构
[1] COLUMBIA UNIV,GERTRUDE H SERGIEVSKY CTR,NEW YORK,NY 10032
[2] COLUMBIA UNIV,COLL PHYS & SURG,DEPT NEUROL,NEW YORK,NY
[3] COLUMBIA UNIV,COLL PHYS & SURG,DEPT PSYCHIAT,NEW YORK,NY
[4] COLUMBIA UNIV,COLL PHYS & SURG,DEPT PHARMACOL,NEW YORK,NY
[5] COLUMBIA UNIV,SCH PUBL HLTH,DIV EPIDEMIOL,NEW YORK,NY
[6] COLUMBIA UNIV,SCH PUBL HLTH,DIV ENVIRONM HLTH SCI,NEW YORK,NY
[7] OSPED MIULLI ACQUAVIVA,DIV NEUROL,BARI,ITALY
关键词
D O I
10.1212/WNL.49.3.714
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Iron deposition in the substantia nigra in Parkinson's disease has been associated with an increase in lactoferrin receptors and a reduction in ferritin concentration. This accumulation of iron in the brain may accelerate free radical formation, lipid peroxidation, and neuronal death. Remarkably, there are few data available concerning systemic iron metabolism in Parkinson's disease. We measured total iron binding capacity and circulating iron, ferritin, transferrin, and transferrin receptors; calculated transferrin saturation; and estimated dietary iron intake in patients with idiopathic Parkinson's disease and in controls. Concentrations of circulating iron, ferritin, and transferrin as well as total iron binding capacity and transferrin saturation were significantly lower in patients than controls. There were no differences in transferrin receptors or dietary intake of iron. The decrease in levels of systemic ferritin and transferrin and the total iron binding capacity parallels observations in a Parkinson's disease brain, but the reductions in serum iron concentrations and transferrin saturation do not, and were unexpected. These results suggest the existence of a defect in the systems that regulate the synthesis of the major proteins of iron metabolism in the liver as well as the brain in Parkinson's disease that may, over time, expedite entry of iron into the brain and decrease iron in the extracellular compartment.
引用
收藏
页码:714 / 717
页数:4
相关论文
共 26 条
[1]  
ABBOTT RA, 1992, EUR J CLIN NUTR, V46, P879
[2]  
*AM PSYCH ASS, 1987, DIAGN STAT MAN MENT, P205
[3]   PERIPHERAL IRON-METABOLISM IN PATIENTS WITH PARKINSONS-DISEASE [J].
CABRERAVALDIVIA, F ;
JIMENEZJIMENEZ, FJ ;
MOLINA, JA ;
FERNANDEZCALLE, P ;
VAZQUEZ, A ;
CANIZARESLIEBANA, F ;
LARUMBELOBALDE, S ;
AYUSOPERALTA, L ;
RABASA, M ;
CODOCEO, R .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1994, 125 (01) :82-86
[4]   FERROUS SULFATE REDUCES LEVODOPA BIOAVAILABILITY - CHELATION AS A POSSIBLE MECHANISM [J].
CAMPBELL, NRC ;
HASINOFF, B .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (03) :220-225
[5]   SINEMET-FERROUS SULFATE INTERACTION IN PATIENTS WITH PARKINSONS-DISEASE [J].
CAMPBELL, NRC ;
RANKINE, D ;
GOODRIDGE, AE ;
HASINOFF, BB ;
KARA, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (04) :599-605
[6]  
CONNOR JR, 1995, J NEUROCHEM, V65, P717
[7]   DECREASED FERRITIN LEVELS IN BRAIN IN PARKINSONS-DISEASE [J].
DEXTER, DT ;
CARAYON, A ;
VIDAILHET, M ;
RUBERG, M ;
AGID, F ;
AGID, Y ;
LEES, AJ ;
WELLS, FR ;
JENNER, P ;
MARSDEN, CD .
JOURNAL OF NEUROCHEMISTRY, 1990, 55 (01) :16-20
[8]   ALTERATIONS IN THE LEVELS OF IRON, FERRITIN AND OTHER TRACE-METALS IN PARKINSONS-DISEASE AND OTHER NEURODEGENERATIVE DISEASES AFFECTING THE BASAL GANGLIA [J].
DEXTER, DT ;
CARAYON, A ;
JAVOYAGID, F ;
AGID, Y ;
WELLS, FR ;
DANIEL, SE ;
LEES, AJ ;
JENNER, P ;
MARSDEN, CD .
BRAIN, 1991, 114 :1953-1975
[9]   EXPRESSION OF LACTOFERRIN RECEPTORS IS INCREASED IN THE MESENCEPHALON OF PATIENTS WITH PARKINSON DISEASE [J].
FAUCHEUX, BA ;
NILLESSE, N ;
DAMIER, P ;
SPIK, G ;
MOUATTPRIGENT, A ;
PIERCE, A ;
LEVEUGLE, B ;
KUBIS, N ;
HAUW, JJ ;
AGID, Y ;
HIRSCH, EC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (21) :9603-9607
[10]   ALTERED BRAIN METABOLISM OF IRON AS A CAUSE OF NEURODEGENERATIVE DISEASES [J].
GERLACH, M ;
BENSHACHAR, D ;
RIEDERER, P ;
YOUDIM, MBH .
JOURNAL OF NEUROCHEMISTRY, 1994, 63 (03) :793-807